Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Balticgruppen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Balticgruppen Bio Starts Bridging Pharmacokinetic & Safety Clinical Trial of a Novel Solid Pharmaceutical Composition of AMPK Activator O304","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Balticgruppen Bio

    Menu

    Balticgruppen Bio

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Balticgruppen Bio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Balticgruppen Bio Starts Bridging Pharmacokinetic & Safety Clinical Trial of a Novel Solid Pharmaceutical Composition of AMPK Activator O304

              Details:

              In previous Phase I and Phase IIa clinical trials in healthy subjects and in type 2 diabetics, the small molecule AMPK activator compound O304 was administered as a suspension and with limited oral bioavailability.

              Lead Product(s): O304-Na,Dapagliflozin

              Therapeutic Area: Endocrinology Product Name: O304-Na

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 17, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY